Shared Care Records in the NHS: What Aspergillosis Patients Need to Know

The NHS is changing how patient records are managed. By 2026, every area of England will have a Shared Care Record. This is not one big “national record,” but a way of securely linking together the different records held by your GP, hospital, and other services.

For patients with aspergillosis, this could make a real difference to care, safety, and research.

🗂 What Is a Shared Care Record?

  • Not one single file: Your GP, hospital, and community services keep their own systems.

  • Linked together: Clinicians can securely view a joined-up picture of your health.

  • Safer and faster care: Your allergies, test results, and medications can be seen wherever you are treated.

  • You tell your story once: No more repeating details every time you see a new doctor.

🛡 How Safe Is My Data?

  • Strict access control: Only staff directly involved in your care can open your record.

  • Audit trail: Every time it’s viewed, the system records who, when, and why.

  • Encryption & firewalls: Records are locked against outside access.

  • No mass downloads: Systems only allow one patient’s record at a time.

In many ways, this is safer than old paper notes, which could be lost, copied, or seen by accident.

👩‍⚕️ Confidentiality Rules Stay the Same

  • NHS staff are bound by confidentiality laws and the Caldicott Principles.

  • Looking at a record without a valid care reason is a disciplinary offence.

  • Your record is not shared with insurers, employers, or relatives without your consent.

📊 Research and Aspergillosis

Shared Care Records could also help improve research into aspergillosis, which is often under-recognised:

  • Better case finding: Linking GP, hospital, and lab data makes it easier to identify true cases.

  • Tracking outcomes: Researchers can follow IgE/IgG results, CT changes, and treatment responses over time.

  • Environmental links: Data could be combined with housing, air quality, and weather information.

  • Support for trials: Easier to find eligible patients for new antifungal or biologic studies.

All research use is usually de-identified (your name and personal details removed). You can choose to opt out via the National Data Opt-Out if you don’t want your data used in this way.

🏦 Will Insurance Companies See My Record?

No. Insurance companies and employers cannot access your NHS record.
If you apply for insurance, your GP may be asked for a report — but this is only done with your consent.

🌐 What If I Don’t Use the Internet?

You don’t need to be online to benefit. Shared Care Records are mainly for clinicians, not for patients logging in.
If you want to see your record, you can still ask for a paper copy from your GP or hospital.

📍 Who Runs Shared Care Records?

They are organised locally by Integrated Care Systems (ICSs).

  • England is divided into 42 ICSs, each bringing together NHS services, local councils, and community care.

  • Examples include Greater Manchester ICS, Cheshire & Merseyside ICS, and North East London ICS.

  • Scotland, Wales, and Northern Ireland use different systems.

✅ Key Reassurances for Patients with Aspergillosis

  • Your data remains confidential and secure.

  • Shared Care Records mean joined-up, safer care across GP, hospital, and community services.

  • Insurers and employers cannot access your NHS record.

  • You stay in control — you can opt out of data use for research if you wish.

  • The new system could help advance aspergillosis research, leading to better diagnosis and treatments.

by GAtherton

🩺 NHS Data Sharing: How It Will Improve Your Care

🌍 The Problem Today

At the moment, your health information is stored in many different places:

  • Your GP (General Practitioner) has one record.

  • Hospitals keep their own records.

  • Community services (like district nurses or physiotherapists) have separate notes.

  • Social care also keeps its own information.

This can cause problems:

  • You may be asked to repeat your story again and again.

  • Doctors don’t always see the full picture (medications, allergies, past test results).

  • Sometimes tests are repeated unnecessarily.

📅 The Timeline for Change

Today (2025)

  • Records are mostly separate.

  • Some areas already share basic information like your medicines and allergies through a “Summary Care Record.”

👉 What it means for you: You still have to repeat information at most appointments.

2026 – Shared Care Records in Every Area

  • Every region (called an Integrated Care System, or ICS) will have a Shared Care Record.

  • This links together information from GPs, hospitals, community teams, and social care.

  • Hospitals using modern systems like Epic (a type of electronic patient record - MFT has installed this already) can also start sharing directly with other Epic hospitals.

👉 What it means for you: Doctors can see more of your health record without asking you to repeat everything.

2028 – Linking Across the Country

  • Regional Shared Care Records will start to connect with each other.

  • Epic hospitals across the UK will share records more easily using Care Everywhere (Epic’s sharing tool).

  • Community services and “virtual wards” (hospital care at home) will be fully connected.

👉 What it means for you: If you are treated in another part of the country, staff there will be able to see important parts of your health record straight away.

2030 – One Joined-Up NHS Record

  • The NHS plans to give every patient a longitudinal record – one joined-up health and care record that follows you everywhere.

  • This will combine information from GPs, hospitals, community services, mental health teams, and social care.

  • Patients will also be able to see much more of their own record through the NHS App.

👉 What it means for you: Wherever you go in the NHS, staff can see your medical history safely. You’ll feel your care is joined-up, and you can also check your record yourself.

✅ Your Patient Journey: Step by Step

  • Today: “I have to explain my medication list every time. I’m not sure my hospital knows what my GP prescribed.”

  • 2026: “When I go into hospital, the doctor can already see my GP record and community nurse notes.”

  • 2028: “I was treated far from home, and the hospital could see my recent test results straight away.”

  • 2030: “Wherever I go, the NHS staff have the full picture. I can see my record too on the NHS App.”

by GAtherton

Damp, Cold, and Poor Housing – Why It Matters for Lung Health

This briefing from the House of Commons Library (2025) looks at how poor housing conditions—especially damp, mould, and cold homes—affect health and what’s being done about it in the UK.

Main Points

  • Health risks are serious
    Living in damp or mouldy homes increases the risk of respiratory problems, particularly for people with existing lung disease like aspergillosis, asthma, COPD, or bronchiectasis.

  • Children and vulnerable adults
    Young children, older adults, and people with weakened immune systems are most affected. Damp and mould can trigger flare-ups, worsen breathing symptoms, and increase infection risk.

  • Mental health impact
    Poor housing is linked to stress, anxiety, and depression. Worrying about your home can also worsen physical symptoms, especially if you avoid using rooms with mould or limit heating to save costs.

  • Cold homes add to the problem
    Cold airways can make breathing more difficult, weaken the immune system, and increase the chance of winter infections.

  • Wider health effects
    Damp and cold can also affect heart health, bone/joint pain, and overall wellbeing.

What’s Being Done

  • Legal responsibilities: Landlords must keep homes safe and fit to live in under UK law. This includes dealing with serious damp and mould.

  • Government programmes:

    • Funding for improving insulation and heating in social housing.

    • Advice services for tenants.

    • Local councils can take action if landlords fail to address hazards.

  • Public health guidance now recognises the link between housing and chronic illness, with stronger advice for early intervention.

What This Means for Aspergillosis Patients

  • Stay alert to symptoms: If your cough, breathlessness, or fatigue worsen at home, check for damp, mould, or poor heating.

  • Act early: Report problems to your landlord or council quickly—prolonged exposure can worsen lung damage.

  • Medical link is recognised: You are more likely to be taken seriously now, as official guidance acknowledges the health risks.

  • Keep records: Photos, symptom diaries, and GP notes can support housing complaints.

For full details see https://commonslibrary.parliament.uk/research-briefings/cdp-2025-0096/

by GAtherton

📘 What is CPA? (Chronic Pulmonary Aspergillosis)

Patient handout for A&E staff who are not aware of aspergillosis.

What is CPA?

CPA is a chronic fungal infection of the lungs caused by Aspergillus, most often in people who already have damaged lungs from conditions like tuberculosis, COPD, lung cancer, or sarcoidosis.

Unlike ABPA, CPA is a true infection, not an allergic reaction. It is not contagious but can slowly destroy lung tissue if not treated.

Symptoms

  • Chronic cough, often with mucus

  • Coughing up blood (haemoptysis)

  • Fatigue, low-grade fever

  • Unexplained weight loss

  • Breathlessness

  • Recurrent chest infections not responding to antibiotics

Diagnosis

  • CT scan of the chest showing cavities, nodules, or fungus balls (aspergillomas)

  • Aspergillus IgG antibody (usually raised)

  • Positive sputum PCR or culture for Aspergillus

  • Exclude TB and malignancy

Treatment

  • Long-term antifungal therapy (e.g. itraconazole, voriconazole, posaconazole)

  • Monitor blood levels and liver function

  • Surgery or embolisation if severe bleeding occurs

  • Supportive care: oxygen, nutrition, physiotherapy

Key Points for A&E:

✅ CPA is a progressive fungal infection, not a typical bacterial pneumonia
✅ May present with haemoptysis, respiratory distress, or systemic illness
✅ Review current antifungal treatment and potential drug interactions
✅ Consider urgent chest CT and specialist referral if patient is unwell

📍 For specialist support:

National Aspergillosis Centre (NAC)
🏥 Wythenshawe Hospital, Manchester University NHS Foundation Trust
🌐 NAC homepage on MFT website  https://mft.nhs.uk/wythenshawe/services/infectious-diseases/national-aspergillosis-centre/
🌐 www.aspergillosis.org

📞 Daytime contact: 0161 291 2891 or 0161 291 4362
📞 Urgent out-of-hours: Call Wythenshawe switchboard on 0161 998 7070
📢 Ask for the on-call Infectious Diseases Consultant

by GAtherton

📘 What is ABPA? (Allergic Bronchopulmonary Aspergillosis)

Patient handout for A&E staff who ask what aspergillosis is.

What is ABPA?

ABPA is an allergic lung condition caused by the immune system overreacting to the fungus Aspergillus. It mainly affects people with asthma or cystic fibrosis.

When Aspergillus spores are inhaled, most people clear them without issue. In ABPA, the immune system sees these spores as dangerous and mounts a strong inflammatory response. This leads to asthma-like symptoms, mucus plugging, and can result in permanent lung damage (bronchiectasis) if left untreated.

Symptoms

  • Worsening breathlessness

  • Wheezing, chest tightness

  • Coughing up thick, often brown mucus

  • Fever, fatigue, or feeling generally unwell

  • Unintentional weight loss (advanced cases)

Diagnosis

  • History of asthma or cystic fibrosis

  • High IgE levels and positive Aspergillus-specific IgE

  • Eosinophilia (raised white blood cells)

  • Sputum culture or PCR positive for Aspergillus

  • Chest imaging showing mucus plugging or bronchiectasis

Treatment

  • Oral corticosteroids (e.g. prednisolone) to reduce inflammation

  • Antifungal medication (e.g. itraconazole) to lower fungal burden

  • Biologic therapies (e.g. omalizumab or benralizumab) in some patients

  • Regular monitoring by respiratory or infectious diseases specialists

Key Points for A&E:

✅ ABPA is an allergic lung disease, not a classical infection
✅ Can present with severe asthma, mucus plugging, or type 2 respiratory failure
✅ Requires early recognition and often systemic steroids and antifungal therapy
✅ Take bloods (IgE, eosinophils, CRP), consider chest imaging, and review oxygen status

📍 For specialist support:

National Aspergillosis Centre (NAC)
🏥 Wythenshawe Hospital, Manchester University NHS Foundation Trust
🌐 NAC homepage on MFT website https://mft.nhs.uk/wythenshawe/services/infectious-diseases/national-aspergillosis-centre/
🌐 www.aspergillosis.org

📞 Daytime contact: 0161 291 2891 or 0161 291 4362
📞 Urgent out-of-hours: Call Wythenshawe switchboard on 0161 998 7070
📢 Ask for the on-call Infectious Diseases Consultant

by GAtherton

🤐 Why It's Important Not to Share Your Clinical Trial Experience — Until It’s Over

If you have chronic pulmonary aspergillosis (CPA), you may be invited to take part in a clinical trial for a new antifungal medication like rezafungin. That’s exciting — and could help improve treatment for many people in future.

Naturally, people want to support each other by sharing experiences, especially in online support groups. But when it comes to clinical trials, there’s a really important reason why we shouldn’t talk about how we’re feeling while we’re still in the trial.

Here’s why.

🧪 What Are Clinical Trials For?

Clinical trials help doctors and researchers answer important questions like:

  • Does this new treatment work?

  • Is it better than the current treatment?

  • What side effects might it cause?

To get accurate answers, the trial needs to be fair and unbiased — meaning that personal expectations and outside influences shouldn’t affect how people report their symptoms or progress.

📣 The Problem With Sharing During a Trial

If you’re taking part in a trial and say something like:

“I feel great — this new drug is working for me!”
or
“This is making me feel worse than ever — don’t join!”

...other people may change how they think and feel based on your comment.

This is called bias. It can:

  • Make others expect the same good (or bad) result

  • Affect how people rate their own symptoms

  • Cause people to drop out or not join at all

  • Make the trial results less accurate or even unusable

Even well-meaning comments can damage the study, especially if the trial is small (like most CPA studies are).

🕵️‍♀️ What If It’s a Blinded Trial?

Some trials are "blinded", meaning you don’t know whether you're getting the new treatment or a standard one (or placebo).

But if people start guessing or posting:

“I’m sure I’m on the real drug — I feel amazing!”

...then other people might also guess, or feel disappointed — which again, affects how results are reported.

🚦When Is It Safe to Share?

💬 After the trial is over and the results are published, you can talk freely about your experience.

In fact, patient voices are vital at that stage — they help others understand what it’s like to be part of a trial and whether new treatments are helpful in real life.

💡 What You Can Say During the Trial

You can still help raise awareness without compromising the study. For example:

  • ✅ “I’m taking part in a CPA trial – ask your doctor if you might be eligible.”

  • ✅ “There’s a study on a new antifungal — here’s the link to the official trial page: clinicaltrials.gov/study/NCT06794554”

  • ✅ “I’m proud to be contributing to research — happy to share my experience once the trial ends.”

Just don’t talk about how the treatment is affecting you until the trial is complete.

🙏 Why This Matters

By keeping quiet during the trial, you're:

  • Protecting the integrity of the study

  • Helping future patients get trustworthy answers

  • Supporting the research team who need clear, unbiased data

You’re not just taking part in a trial — you’re helping build evidence that others will depend on for years to come.

🧭 Summary

✅ Do ❌ Don’t
Tell people a trial exists Share how the treatment is affecting you
Encourage others to talk to their doctor Post guesses about which drug you’re on
Wait until the trial ends to share experiences Influence others to join based on your results

If you're ever unsure, ask your clinical trial team or group moderator — they'll be glad to help. Your role in research is important, and your silence now is a powerful act of support for science, fairness, and future care.

by GAtherton

💙 Disability Verification and Support for People with Aspergillosis in the UK

Living with aspergillosis—whether it's chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), or another form—can have a significant impact on daily life. Many people find that fatigue, breathlessness, medication side effects, and other long-term symptoms affect their ability to work, care for themselves, or maintain independence.

If your condition is affecting your daily activities, you may be entitled to disability support, financial help, or adjustments at work or home. This guide explains how to get your disability recognised and verified in the UK, who can help, and how this varies across age groups and types of disability.

✅ What Counts as a Disability?

Under the Equality Act 2010, a person is classed as disabled if they have:

“A physical or mental impairment that has a substantial and long-term negative effect on their ability to carry out normal day-to-day activities.”

Many people with aspergillosis meet this definition—especially if they experience breathlessness, fatigue, pain, or recurrent infections over months or years.

📋 How Can You Prove or Verify Your Disability?

There is no single "disability certificate" in the UK. Instead, different systems accept different types of evidence, depending on what support you are applying for.

1. Benefit Award Letters

These are the most commonly accepted form of disability evidence:

  • Personal Independence Payment (PIP)
  • Disability Living Allowance (DLA) (for under 16s)
  • Attendance Allowance (for over State Pension age)
  • Employment and Support Allowance (ESA) (Support Group)
  • Industrial Injuries Disablement Benefit

Where to get it: Contact the DWP or check your online account for a copy of your award letter.

2. NHS Medical Letters

Ask your GP or consultant to write a letter that:

  • Confirms your diagnosis (e.g. CPA, ABPA)
  • Describes the symptoms and how they affect your daily life
  • Explains any treatments you need (e.g. antifungals, oxygen, steroids)
  • States any long-term prognosis or care needs

3. Blue Badge and Disabled Bus Pass

  • Blue Badge: Available from your local council for parking needs
  • Disabled Bus Pass: Also issued locally; often requires proof of benefits or medical need

4. Occupational Therapy Assessment

  • NHS or council-based OTs can assess your ability to manage daily tasks and recommend adaptations or support.
  • Access via GP or Adult Social Care team.

5. Workplace or Education Support

  • Occupational Health assessments may recommend reasonable adjustments such as flexible hours, remote work, or cleaner air environments.
  • You may be eligible for Access to Work grants.

6. PIP and Other Benefit Assessments

  • Assessments focus on how your condition affects daily tasks like mobility, personal care, medication management, and communication.

🔢 Do We Get a Disability Percentage?

In the UK, disability is not usually measured as a percentage. Most systems use functional assessments or point-based scoring.

The Exception: Industrial Injuries Disablement Benefit (IIDB)

  • Uses a percentage system based on the extent of permanent disablement from a work-related condition.

For Everyone Else:

  • PIP, DLA, and ESA use points-based systems.
  • Employers, schools, and councils assess need based on impact, not percentage.

🡥 Who Can Help You with Disability Assessment?

Professional / Service Role & When to Use
GP or Specialist Consultant Confirm diagnosis and functional impact for letters and forms
Occupational Therapist (NHS) Assess your ability to manage daily tasks, recommend home aids/adaptations
Occupational Health (Work) Recommend workplace adjustments under Equality Act
Adult Social Care (Council) Assess for care support and home adaptation funding
Citizens Advice / Disability Charities Help with forms, appeals, and understanding your rights
National Aspergillosis Centre (NAC) May provide supporting letters for housing or benefits if you're under their care

👶 Children and Young People

Under 16

  • Claim Disability Living Allowance (DLA)
  • Apply for an Education, Health and Care Plan (EHCP) if they have learning or developmental needs
  • Get support from social care and school SENCOs

Age 16–25

  • Transition to PIP for disability benefits
  • EHCP can continue to age 25 if still in education
  • Access workplace/education adjustments and Access to Work
  • Shift from Children’s Services to Adult Social Care at 18

👵 Older Adults (Typically Age 65+)

Attendance Allowance

  • For care needs only (not mobility)
  • Not means-tested

Care and Support Needs

  • Request a Care Act assessment from local council
  • May result in home care, adaptations, or care home funding

NHS Continuing Healthcare

  • For those with severe, complex needs
  • Fully funded by NHS; not means-tested

Blue Badge Scheme

  • Still accessible based on breathlessness or mobility limitation

Carer Support

  • Carer's Assessment available
  • Access to Carer’s Allowance or respite care

🧠 Mental Illness and Long-Term Invisible Disabilities

Mental health conditions and other non-visible disabilities (e.g. chronic fatigue, fibromyalgia, autism, long COVID) are also recognised under the Equality Act if they are long-term and impact daily life.

Differences in Assessment

  • Focus is on non-physical activities:
    • Planning and following journeys
    • Managing therapy or medication
    • Social interaction
    • Decision-making

Key Evidence

  • GP letters
  • Psychiatrist or psychologist reports
  • Occupational therapy or carer evidence

Support Services

  • Community mental health teams (CMHT)
  • Crisis teams, counselling, and talking therapies
  • Supported housing or assisted living

Reasonable Adjustments

  • Flexible schedules, quiet spaces, remote work
  • Mental health support plans at school, university, or work

Advocacy

  • Mind, Rethink, Disability Rights UK, and VoiceAbility provide advocacy, appeals help, and representation

📚 Summary Table

Area Physical Disabilities Mental Health / Invisible Disability Children Older Adults
Benefit PIP / ESA PIP / ESA DLA Attendance Allowance
Social Care Adult Social Care assessment Adult Social Care or MH services Children’s Services Adult Social Care
Education/Work Support Access to Work, OH reports Access to Work, reasonable adjustments EHCP, SENCO Retirement/flexible options
Blue Badge Based on mobility Based on anxiety/severe distress for travel May be available Common for respiratory limits
Evidence Needed Consultant, OT, GP Psychiatrist, GP, carer, advocate School or paediatric reports GP, consultant, OT
Advocacy Support Citizens Advice, Scope Mind, Rethink, Disability Rights UK IPSEA, Contact Age UK, Carers UK

🙏 Final Tips

  • Keep copies of all letters, forms, and award notices.
  • If your condition fluctuates, keep a symptom diary to show variable impact.
  • Apply for assessments early as processes can take time.
  • If you need help applying, speak to Citizens Advice or a local disability advocacy service.
  • The National Aspergillosis Centre may be able to support patients with evidence for housing, benefit, or support applications.

by GAtherton

🫁 Mucus Plugging in Aspergillosis: What It Is, Why It Happens, and What It Means

For patients with ABPA, CPA, Aspergillus bronchitis, or asthma

🔍 What Is a Mucus Plug?

A mucus plug is a thick clump of sticky mucus that becomes trapped in your lungs. It can block airways, cause coughing, and make breathing more difficult. In people with aspergillosis, this is common — but the type, location, and cause of the mucus can vary.

🧪 What Causes Mucus Plugging?

Your lungs naturally make mucus to protect against germs and irritants. But in fungal or allergic lung disease, this mucus may:

  • Be produced in excess

  • Become too thick or sticky

  • Get trapped due to airway damage

Aspergillosis-related causes include:

  • ABPA (Allergic Bronchopulmonary Aspergillosis) – inflammation causes thick, sticky mucus

  • Aspergillus bronchitis – fungus lives in mucus, producing biofilms

  • CPA (Chronic Pulmonary Aspergillosis) – may lead to mucus due to structural damage

  • Bronchiectasis – airways are widened and can no longer clear mucus properly

🧬 Are All Mucus Plugs the Same?

No. Mucus plugs vary in colour, texture, cause, and treatment. Here's how they differ:

Type of Plug What You Might See What It Could Mean Common in...
Sticky, stringy Clear/yellow, like glue Allergic inflammation ABPA, asthma
Rubbery or solid Brown, rubbery, “slug-like” Allergic + fungal mix ABPA, Aspergillus bronchitis
Green or smelly Thick, foul-smelling Infection (bacteria) Bronchiectasis
Foamy or frothy Clear/white, bubbly Non-infectious irritation COPD, asthma
Black or speckled May contain fungal specks Fungal growth CPA, fungal bronchitis

🖼️ What Do Mucus Plugs Look Like on a CT Scan?

Below are real examples of CT scan findings showing mucus plugging in different forms of aspergillosis and related conditions.

🧷 1. Finger-in-glove sign (ABPA)

Mucus in large airways appears like fingers inside a glove. This is common in allergic fungal airway disease.

➡ Seen in: ABPA, bronchiectasis with fungal colonisation
📍 Note: Branching tubular opacities filled with mucus.

🌿 2. Tree-in-bud pattern

Small airway blockage — plugs in the tiniest branches of the lungs. Common in infection, inflammation, and Aspergillus bronchitis.

➡ Seen in: Aspergillus bronchitis, asthma, CPA with superinfection
📍 Note: Tiny dots and lines in a tree-like shape.

🧱 3. Lung collapse (atelectasis) from plug

A large mucus plug can block a main airway, causing collapse of part of the lung.

➡ Seen in: Severe ABPA, CPA, patients with weakened cough reflex
📍 Note: Whiteout of part of lung where plug is blocking airflow.

📸 Example CT Findings

 

1. Bronchiectasis + mucus plug
Area in the left lower lung shows dilated bronchi filled with mucus—classic for bronchiectasis with mucoid impaction

2. Extensive bronchiectasis with plugs
Widespread thick-walled airway dilatation accompanied by mucus plugs (black arrows) and consolidation (black arrowheads)

3. Luminal plugging in small airways
Subtle luminal opacities in peripheral bronchi—the “tree‑in‑bud” pattern common in asthma, COPD, and infections.

4. Atelectasis (part of the lung has collapsed or isn’t fully inflating) due to mucus plugging
Consolidation and small airway blockage leading to lung collapse, highlighted by arrows in the upper lobe.

💡 Clinical Takeaways

Feature What it indicates
Mucoid impaction Large airway fungal/allergic plugs (e.g., ABPA) or bronchiectasis
Tree‑in‑bud Small-airway infection/inflammation (e.g., TB, PCD, asthma)
Atelectasis Complete blockage, leading to collapse and consolidation
Persistent luminal plugs Associated with worse airflow obstruction and symptoms in COPD/asthma

✅ Next Steps / Applications

  • These CT examples are valuable for educational use—they illustrate the different patterns seen in mucus plugging across disease types.

  • Radiologists often use these signs to help diagnose and tailor management (infection, allergy, structural lung disease).

  • If your patients or students need simplified visuals, these scans paired with annotations (e.g., arrows, labels) can make great teaching tools.

🧠 What Does It Feel Like?

People often say:

“It felt like something was stuck and wouldn’t come out.”
“I finally coughed up a rubbery strand — like glue.”
“Once it cleared, I could breathe better instantly.”

🧼 How Are Mucus Plugs Treated?

Treatment depends on the underlying cause:

✅ Medications

  • Steroids – reduce inflammation in ABPA and asthma

  • Antifungals – lower fungal load (e.g., itraconazole, posaconazole)

  • Mucolytics – thin mucus (e.g., carbocisteine, hypertonic saline)

  • Antibiotics – treat bacterial infections

✅ Airway Clearance Techniques

  • Respiratory physio – helps you learn how to shift mucus

  • Devices – flutter valve, PEP mask, Acapella

  • Inhaled/nebulised therapy – opens airways and loosens plugs

⚠️ Always speak to your clinical team before starting a new technique.

🧪 Can Coughing Up a Plug Help Diagnosis?

Yes! If you cough up a rubbery, large, or unusual plug, it can be:

  • Tested for fungus, bacteria, or allergy cells (eosinophils)

  • Sent for culture to detect Aspergillus

  • Helpful in guiding or confirming diagnosis of ABPA or Aspergillus bronchitis

👣 Key Points for Aspergillosis Patients

Question Answer
Is mucus plugging common? Yes, especially in ABPA, CPA, and bronchiectasis
Are all mucus plugs the same? No – they vary in size, shape, colour, and cause
What should I do if I cough one up? Tell your doctor – it may be useful to test
Can it be seen on scans? Yes – CT can show where plugs are and how severe
Can it be treated? Yes – treatments include steroids, antifungals, mucolytics, and physio

by GAtherton

Other forms of Aspergillosis: 🔬 Acute Invasive Aspergillus Sinusitis (AIAFS)

⚠️ A rare and severe fungal sinus infection — seen almost exclusively in people with severely weakened immune systems

🧾 What is it?

Acute Invasive Aspergillus Sinusitis (AIAFS) is a rapidly progressing fungal infection of the sinuses, caused by Aspergillus species (typically A. fumigatus). It leads to tissue invasion, destruction, and potentially fatal complications if not treated urgently.

🛡️ Who is at Risk of Acute Invasive Aspergillus Sinusitis?

Acute Invasive Aspergillus Sinusitis (AIAFS) is very rare, and affects people who are significantly immunocompromised — meaning their immune systems are unable to control even common environmental fungi.
However, “immunocompromised” is not always black-and-white. There are different degrees of vulnerability, and it's important to understand who is at greatest risk.

🔴 High-risk (severe immunosuppression)

These individuals are at the greatest risk for AIAFS:

  • Profound neutropenia (especially <500 neutrophils/μL for >10 days)

  • Acute leukaemia or stem cell transplantation

  • Solid organ transplant recipients on strong immunosuppressive regimens

  • High-dose corticosteroids (e.g. ≥20 mg prednisolone/day for ≥2 weeks)

  • Uncontrolled HIV/AIDS with low CD4 counts (<200)

  • Diabetic ketoacidosis or severe metabolic acidosis

🟠 Intermediate-risk (chronic or moderate immunosuppression)

Patients in this category may not be at risk of AIAFS, but may still be more vulnerable to chronic or allergic forms of aspergillosis or other infections:

  • Long-term oral corticosteroids at lower doses (e.g. <10 mg/day)

  • Biologic therapies for asthma (e.g. anti-IL-5, anti-IgE), which may subtly modulate immunity

  • Genetic susceptibility (e.g. subtle immune pathway deficiencies identified in CPA or ABPA)

  • COPD, bronchiectasis or severe asthma with impaired local defence

  • Malnutrition or poorly controlled diabetes

These patients are not typically at risk of invasive sinus aspergillosis, but may experience worsening of fungal conditions or atypical presentations of infection.

🟢 Low-risk (normal immune function)

People with normal immune function — even those with:

  • Allergic rhinitis

  • Chronic rhinosinusitis

  • Mild asthma or occasional infections

…are not at risk of developing AIAFS. Everyday exposure to Aspergillus spores is harmless to most people.

💬 Key Clarification:

Having aspergillosis does not automatically mean you are at risk of invasive sinus infection.
Many patients with CPA, ABPA, or SAFS are immunologically “fragile,” but not severely immunocompromised.
AIAFS typically only occurs in people with a combination of immune suppression and a very specific set of risks — especially when white blood cell function is severely impaired.

📋 Symptoms and Signs (typically <4 weeks onset)

  • Fever that does not respond to antibiotics

  • Facial pain or pressure, often severe and one-sided

  • Nasal congestion, discharge (often bloody or blackish)

  • Dark scabs (eschar) on the nasal mucosa or palate

  • Eye swelling, visual changes, or cranial nerve symptoms (if spread to the orbit or brain)

  • Altered mental state, seizures (in advanced cases)

🧪 Diagnosis

AIAFS is diagnosed based on:

  • Clinical suspicion in a high-risk patient

  • Endoscopic examination with biopsy and histology (showing hyphal invasion of tissue)

  • CT/MRI imaging to assess spread (bone, orbit, brain)

  • Culture and molecular testing of sinus material

  • Aspergillus PCR or galactomannan testing may help, but are not definitive alone

💊 Treatment Approach

Treatment must begin urgently, ideally within hours of suspicion.

1. Systemic antifungal therapy

  • First-line: Voriconazole or Isavuconazole

  • Alternatives: Liposomal Amphotericin B

  • Combination therapy may be considered in some cases

  • Therapeutic drug monitoring is essential (especially for voriconazole)

2. Surgical debridement

  • Prompt and aggressive endoscopic surgery is critical

  • Repeat procedures may be needed to remove necrotic tissue

3. Immunological support

  • Reversal of neutropenia if possible (e.g. G-CSF)

  • Reduction or withdrawal of immunosuppressive drugs

  • Management of underlying condition (e.g. glycaemic control in diabetes)

📈 Prognosis

  • Mortality is high (>50%) if not recognised and treated early

  • With rapid antifungal therapy and surgery, survival improves significantly

  • Regular monitoring, follow-up imaging, and immune recovery are crucial to long-term outcomes

🧠 Key Points to Remember

✅ This is a medical emergency, but
✅ It is extremely rare, and
✅ Almost exclusively affects those with profound immune suppression
✅ Not a risk to the general public or people with typical sinus infections

📣 Summary for Patient Awareness

Acute Invasive Aspergillus Sinusitis is very rare.
It is a fast-moving sinus infection caused by a fungus called Aspergillus, but it only happens in people with very weak immune systems, like those having chemotherapy or organ transplants.
It needs urgent treatment with antifungal medicine and sometimes surgery.
If your immune system is normal, this infection is not a risk to you.

by GAtherton

Aspergillosis Awareness: Conversation with Tom Bermingham - European Lung Foundation

Conversation with Tom Bermingham - European Lung Foundation

👨 Meet Tom Bermingham

  • Lives in rural County Wexford, Ireland, with his wife.

  • Works as a Rural Development Manager.

  • Diagnosed with aspergillosis in 2022 after years of lung issues.

🌪️ What Triggered His Aspergillosis

  • He grew sunflowers in a polytunnel; handling decaying heads released dust he inhaled.

  • Later, home renovation stirred up bathroom mould/dust—both likely exposures.

🏥 The Path to Diagnosis

  • 2019: Hospitalised for cavitating pneumonia and diagnosed with bronchiectasis.

  • Later treated for chronic fatigue syndrome, repeated infections, tiring quickly.

  • Feb 2022: Hospitalised again (17 days), diagnosed with severe adult-onset asthma, oxygen-dependent, with mucus positive for Aspergillus fumigatus.

  • Initially labelled with Chronic Pulmonary Aspergillosis (CPA), treated with steroids, antifungals, inhalers, antibiotics, and fatigue medications.

  • 2024: Diagnosis revised to ABPA + Severe Asthma with Fungal Sensitisation (SAFS).

  • October 2024: Hospitalised for COVID-19 and Pseudomonas lung infection treated via PICC line. European Lung Foundation

💔 How It Affects His Daily Life

  • Mornings bring coughing up “dirty mucus” daily—an unsettling reminder.

  • Extreme fatigue, headaches, regular infections dominate his life.

  • Gave up gardening (risk of soil exposure), community work, and physical chores.

  • Lives with constant fear of infection, medication side effects, and hospitalisations.

  • Chronic disease has made long-term planning impossible; relaxation and mental wellbeing are vital.

🧭 How He Manages

  • Supported by his wife and daughters and his flexible employer.

  • Practices listening to his body: rests when needed.

  • Regular check-ups—including CT scans, lung function, sputum and blood tests—keep his care monitored. European Lung Foundation

  • Accepting limitations while focusing on what he can still do helps his mindset.

✅ Key Insights for Aspergillosis Patients

  • Environmental exposures matter: mould, dust, soil may trigger illness—even long after.

  • Diagnosis can be complex and evolve: often overlaps with asthma, bronchiectasis, ABPA, SAFS.

  • Daily life can change significantly, with physical decline and emotional stress.

  • Support network and personalised care are crucial—family, employer flexibility, specialist monitoring.

  • Self-care and mindset: acceptance, rest, and focusing on abilities, not limitations.

by GAtherton